162 related articles for article (PubMed ID: 21832981)
1. New clinical trials with vitamin D and analogs in renal disease.
Kumar R
Kidney Int; 2011 Oct; 80(8):793-6. PubMed ID: 21832981
[TBL] [Abstract][Full Text] [Related]
2. Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition.
Kim MJ; Frankel AH; Donaldson M; Darch SJ; Pusey CD; Hill PD; Mayr M; Tam FW
Kidney Int; 2011 Oct; 80(8):851-60. PubMed ID: 21832985
[TBL] [Abstract][Full Text] [Related]
3. Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol.
Hansen D; Brandi L; Rasmussen K
BMC Nephrol; 2009 Sep; 10():28. PubMed ID: 19778452
[TBL] [Abstract][Full Text] [Related]
4. A randomised clinical study of alfacalcidol and paricalcitol.
Hansen D
Dan Med J; 2012 Feb; 59(2):B4400. PubMed ID: 22293059
[TBL] [Abstract][Full Text] [Related]
5. No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial.
Hansen D; Rasmussen K; Danielsen H; Meyer-Hofmann H; Bacevicius E; Lauridsen TG; Madsen JK; Tougaard BG; Marckmann P; Thye-Roenn P; Nielsen JE; Kreiner S; Brandi L
Kidney Int; 2011 Oct; 80(8):841-50. PubMed ID: 21832979
[TBL] [Abstract][Full Text] [Related]
6. Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients.
Zheng JQ; Hou YC; Zheng CM; Lu CL; Liu WC; Wu CC; Huang MT; Lin YF; Lu KC
Nutrients; 2016 Nov; 8(11):. PubMed ID: 27827962
[TBL] [Abstract][Full Text] [Related]
7. Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis.
Fiedler R
Clin Drug Investig; 2007; 27(12):865-6. PubMed ID: 18020546
[No Abstract] [Full Text] [Related]
8. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol.
Hansen D; Rasmussen K; Pedersen SM; Rasmussen LM; Brandi L
Nephrol Dial Transplant; 2012 Jun; 27(6):2263-9. PubMed ID: 22140123
[TBL] [Abstract][Full Text] [Related]
9. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.
de Zeeuw D; Agarwal R; Amdahl M; Audhya P; Coyne D; Garimella T; Parving HH; Pritchett Y; Remuzzi G; Ritz E; Andress D
Lancet; 2010 Nov; 376(9752):1543-51. PubMed ID: 21055801
[TBL] [Abstract][Full Text] [Related]
10. Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis.
Rosery H; Bergemann R; Marx SE; Boehnke A; Melnick J; Sterz R; Williams L
Clin Drug Investig; 2006; 26(11):629-38. PubMed ID: 17163297
[TBL] [Abstract][Full Text] [Related]
11. [Cholecalciferol supplementation improves secondary hyperparathyroidism control in hemodialysis patients].
Massimetti C; Bellasi A; Feriozzi S
G Ital Nefrol; 2020 Jun; 37(3):. PubMed ID: 32530156
[No Abstract] [Full Text] [Related]
12. Vitamin D metabolites and/or analogs: which D for which patient?
Mazzaferro S; Goldsmith D; Larsson TE; Massy ZA; Cozzolino M
Curr Vasc Pharmacol; 2014 Mar; 12(2):339-49. PubMed ID: 23713876
[TBL] [Abstract][Full Text] [Related]
13. Microalbuminuria, another use for paricalcitol? Our experience in advanced chronic kidney disease.
Blanco-García R; Bravo-López JJ; Moreiras-Plaza M; Nájera-de la Garza W; Cossio-Annibar C; Beato-Coo L; Rodríguez-Goyanes G
Nefrologia; 2012 May; 32(3):401-2. PubMed ID: 22592429
[No Abstract] [Full Text] [Related]
14. Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials.
Xie Y; Su P; Sun Y; Zhang H; Zhao R; Li L; Meng L
BMC Nephrol; 2017 Aug; 18(1):272. PubMed ID: 28841848
[TBL] [Abstract][Full Text] [Related]
15. Effect of Vitamin D therapy on urinary albumin excretion, renal functions, and plasma renin among patients with diabetic nephropathy: A randomized, double-blind clinical trial.
Liyanage P; Lekamwasam S; Weerarathna TP; Liyanage C
J Postgrad Med; 2018; 64(1):10-15. PubMed ID: 29386413
[TBL] [Abstract][Full Text] [Related]
16. Low-dose cholecalciferol supplementation and dual vitamin D therapy in haemodialysis patients.
Dusilová-Sulková S; Šafránek R; Vávrová J; Horáček J; Pavlíková L; Palička V
Int Urol Nephrol; 2015 Jan; 47(1):169-76. PubMed ID: 25262147
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
[TBL] [Abstract][Full Text] [Related]
18. Oral supplementation with cholecalciferol 800 IU ameliorates albuminuria in Chinese type 2 diabetic patients with nephropathy.
Huang Y; Yu H; Lu J; Guo K; Zhang L; Bao Y; Chen H; Jia W
PLoS One; 2012; 7(11):e50510. PubMed ID: 23209764
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease.
Tarrass F; Yazidi A; Sif H; Zamd M; Benghanem MG; Ramdani B
Clin Nephrol; 2006 Jun; 65(6):415-8. PubMed ID: 16792136
[TBL] [Abstract][Full Text] [Related]
20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
